Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer
April 23rd, 2008
Antigenics Inc. (NASDAQ: AGEN) announced that the Russian Ministry of Public Health has issued a registration certificate for the use of Oncophage(R) (vitespen) in the treatment of kidney cancer patients at intermediate risk for disease recurrence. The company expects to launch Oncophage in Russia in the second half of 2008. "The registration of Oncophage in Russia represents an important treatment advancement for patients with intermediate-risk kidney cancer," said Garo H. Armen, PhD, chairman and CEO of Antigenics. "We are very pleased that Oncophage is the first personalized cancer vaccine that will be available in any major country. Additionally we hope to file for...
Source: Vaccine Weekly (2008-04-23)
|
